We are live on ! Find out more
VTAE

VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE

Delisted

VTAE was delisted on the 24th of October, 2016.

Back to rankings

78 hedge funds and large institutions have $137M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2016 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 19

13% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 16

3% more funds holding

Funds holding: 76 → 78 (+2)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

52% less capital invested

Capital invested by funds: $284M → $137M (-$148M)

Holders
78
Holders Change
+2
Holders Change %
+2.63%
% of All Funds
2.08%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
18
Increased
32
Reduced
19
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$11.4M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$11.4M
3
CAM
Cormorant Asset Management
Massachusetts
+$10.1M
4
DCM
DAFNA Capital Management
California
+$5.4M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.32M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$8.82M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.8M
3
DCM
Driehaus Capital Management
Illinois
-$4.4M
4
PA
Perceptive Advisors
New York
-$3.62M
5
Millennium Management
Millennium Management
New York
-$3.61M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
51
Citadel Advisors
Florida
$149K -$17.8K -1,960 -8%
MIM
52
Monashee Investment Management
Massachusetts
$133K – – –
SO
53
STRS Ohio
Ohio
$125K – – –
SIM
54
Spark Investment Management
New York
$121K +$16.4K +1,800 +11%
ProShare Advisors
55
ProShare Advisors
Maryland
$117K -$16.6K -1,821 -9%
VEA
56
Virtus ETF Advisers
New York
$116K +$159K +17,530 New
RhumbLine Advisers
57
RhumbLine Advisers
Massachusetts
$85K +$909 +100 +0.8%
New York State Common Retirement Fund
58
New York State Common Retirement Fund
New York
$80K – – –
Citigroup
59
Citigroup
New York
$79K +$46.5K +5,108 +76%
Susquehanna International Group
60
Susquehanna International Group
Pennsylvania
$77K +$106K +11,660 New
DTL
61
Dynamic Technology Lab
Singapore
$70K +$96.3K +10,588 New
Wells Fargo
62
Wells Fargo
California
$69K +$29.3K +3,227 +46%
BCM
63
Bridgeway Capital Management
Texas
$67K – – –
Manulife (Manufacturers Life Insurance)
64
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$60K +$3.52K +387 +4%
AIG
65
American International Group
New York
$52K – – –
BA
66
BlackRock Advisors
Delaware
$38K – – –
Deutsche Bank
67
Deutsche Bank
Germany
$32K -$10.2K -1,116 -18%
BlackRock
68
BlackRock
New York
$11K +$14.3K +1,577 +777%
Bank of America
69
Bank of America
North Carolina
$9K -$28K -3,078 -70%
UBS Group
70
UBS Group
Switzerland
$7K – – –
TRCT
71
Tower Research Capital (TRC)
New York
$5K +$464 +51 +7%
GWM
72
Gupta Wealth Management
California
$4K – – –
MA
73
MUFG Americas
New York
$2K +$2.09K +230 New
BNP Paribas Financial Markets
74
BNP Paribas Financial Markets
France
$1.09K -$22.3K -2,454 -94%
Bank of Montreal
75
Bank of Montreal
Ontario, Canada
$1K -$77.1K -8,472 -98%
1 2
3
4

VTAE Hedge Fund Activity: Q1 2016 in Review

78 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q1 2016, worth a combined $137M — down 52% from $284M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new VTAE positions and 16 closed out — a net gain of 2 holders — while 32 added to existing stakes and 19 trimmed.

The largest buyer was RA Capital Management, adding an estimated $11.4M. The largest seller was OrbiMed, exiting entirely with an estimated $8.82M sold.

  • 78 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q1 2016, up from 76 in Q4 2015.
  • Funds reported $137M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q1 2016, down 52% quarter-over-quarter.
  • 18 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q1 2016 and 16 closed out, a net change of +2 holders.
  • The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q1 2016 was RA Capital Management, an estimated $11.4M added.
  • The largest VITAE PHARMACEUTICALS INC COMMON STOCK seller in Q1 2016 was OrbiMed, an estimated $8.82M sold.

Based on aggregated 13F filings for Q1 2016.